Brief review on ongoing clinical trials on covid-19 vaccines
Abstract
Five years into mass deployment, COVID-19 vaccine R&D remains active, with trials now concentrating on variant-adapted boosters, mucosal (intranasal/oral) candidates aimed at blocking transmission, and broadly protective (pan-coronavirus) vaccines. Recent Phase 1–3 studies are refining antigen choice (e.g., KP.2/JN.1-era variants), delivery routes, and durability, while expanding evaluation in older adults and other high-risk groups. This review summarizes the current clinical pipeline and trial directions using the WHO vaccine landscape, ClinicalTrials.gov records, and recent peer-reviewed reports.
DOI
https://doi.org/10.70604/References
1. World Health Organization (WHO). COVID-19 vaccine tracker and landscape [Internet]. Geneva: WHO; 2025 [cited 2025 Aug 29]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
2. ClinicalTrials.gov. RNA-based variant-adapted booster (Pfizer/BioNTech) [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2025. Report No.: NCT07069309. Available from: https://clinicaltrials.gov/study/NCT07069309
3. ClinicalTrials.gov. Moderna mRNA-1283 2025–2026 formula [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2025. Report No.: NCT07089706. Available from: https://clinicaltrials.gov/study/NCT07089706
4. ClinicalTrials.gov. Novavax rS + Matrix-M, booster/updates [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2025. Report No.: NCT04583995. Available from: https://clinicaltrials.gov/study/NCT04583995
5. Zhang J, Liu Y, Wang Y, et al. Phase 1 randomized trial of intranasal dNS1 vaccine in children. NPJ Vaccines. 2025;10:56. doi:10.1038/s41541-025-00798-2
6. Washington University School of Medicine. Intranasal COVID-19 vaccine to enter U.S. clinical trials [Internet]. St. Louis: WUSM; 2025 [cited 2025 Sep 1]. Available from: https://medicine.wustl.edu/news/intranasal-covid-19-vaccine-to-enter-u-s-clinical-trials/
7. ClinicalTrials.gov. Vaxart oral tablet VXA-CoV2-3.3 [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2025. Report No.: NCT06672055. Available from: https://clinicaltrials.gov/study/NCT06672055
8. Salgado-Ruiz D, Ramirez M, et al. Patria (AVX/COVID-12) Phase 2 booster—intranasal/intramuscular study. Vaccine. 2024;42(15):2091–8. doi:10.1016/j.vaccine.2024.03.015
9. ClinicalTrials.gov. Pancoronavirus vaccine Phase 1 study [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2025. Report No.: NCT06950177. Available from: https://clinicaltrials.gov/study/NCT06950177
10. ClinicalTrials.gov. CD40.Pan.CoV Phase 1/2a study [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2025. Report No.: NCT07113106. Available from: https://clinicaltrials.gov/study/NCT07113106
11. ANRS–MIE; Inserm. LKV-PAN-01 (PanCoV) clinical trial announcement [Internet]. Paris: ANRS–MIE; 2025 [cited 2025 Sep 1]. Available from: https://anrs.fr/en/newsroom/lkv-pan-01-study-launch/
12. Center for Infectious Disease Research and Policy (CIDRAP). Coronavirus vaccines R&D roadmap [Internet]. Minneapolis: CIDRAP; 2025 [cited 2025 Sep 1]. Available from: https://www.cidrap.umn.edu/coronavirus-vaccines-rd-roadmap
13. Lee S, Johnson H. Evolving vaccine timelines for the 2024/2025 season. Vaccine [Internet]. 2024;42(9):1532–40. Available from: https://doi.org/10.1016/j.vaccine.2024.01.012
Published
Abstract Display: 21 
PDF Downloads: 16 How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
.